Neumora Therapeutics (NMRA) Retained Earnings (2022 - 2026)

Neumora Therapeutics' Retained Earnings history runs 5 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 21.91% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 21.91% YoY), while the FY2025 annual figure was -$1.2 billion, down 25.01% from the prior year.
• Retained Earnings was -$1.2 billion for Q1 2026 at Neumora Therapeutics, down from -$1.2 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$311000.0 in Q3 2023 to a low of -$1.2 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$811.9 million across 5 years, with a median of -$917.8 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings slumped 285559.81% in 2024, then fell 21.91% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$774000.0 in 2022, then sank by 90782.95% to -$703.4 million in 2023, then slumped by 34.66% to -$947.2 million in 2024, then dropped by 25.01% to -$1.2 billion in 2025, then declined by 4.51% to -$1.2 billion in 2026.
• The last three Retained Earnings figures came in at -$1.2 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.